Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review
The follow-up treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation after drug resistance to EGFR-tyrosine kinase inhibitors (TKIs) have become a hotspot and difficulty at present. Immune checkpoint inhibitors (ICIs) therapy is a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Language: | Chinês |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2022-08-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.37 |
| Tags: |
No Tags, Be the first to tag this record!
|